# hl7.org.nz.fhir.ig.cca#0.1.0: HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide

## Pages

* [Home](index.md)
* [Terminology](terminology.md)
* [Artifacts Summary](artifacts.md)
* [Extensions](extensions.md)
* [Capability Statement](CapabilityStatement.md)
* [Notes](notes.md)
* [Profiles](profiles.md)
* [Examples](examples.md)

## Resources

### CodeSystems

* [ESMO-MCBS Evaluation Form](CodeSystem-sact-esmo-mcbs-evaluation-form.md)
* [PlanDefinition additional status](CodeSystem-sact-plan-definition-status-code.md)
* [Regimen type code](CodeSystem-sact-regimen-code.md)
* [Treatment setting](CodeSystem-sact-treatment-setting-code.md)

### ValueSets

* [Cancer type](ValueSet-cancer-type-code.md)
* [Administration location](ValueSet-sact-administration-site-code.md)
* [Medication dose administration frequency](ValueSet-sact-dose-administration-frequency.md)
* [Medication dose unit](ValueSet-sact-dose-unit-code.md)
* [ESMO-MCBS Evaluation Form](ValueSet-sact-esmo-mcbs-evaluation-form.md)
* [Medication collection location](ValueSet-sact-location-medication-collection-code.md)
* [PlanDefinition additional status](ValueSet-sact-plan-definition-status-code.md)
* [Regimen type code](ValueSet-sact-regimen-code.md)
* [Route](ValueSet-sact-route.md)
* [Support Factors](ValueSet-sact-support-factor-code.md)
* [Possible values for Support Factors](ValueSet-sact-support-factor-value-code.md)
* [Treatment setting](ValueSet-sact-treatment-setting-code.md)

### Logicals

* [CancerRegimensLM](StructureDefinition-CancerRegimensLM.md)

### Complex-type Profiles

* [Dosage](StructureDefinition-CcaDosage.md)

### Resource Profiles

* [ActivityDefinition](StructureDefinition-CcaActivityDefinition.md)
* [PlanDefinition](StructureDefinition-CcaPlanDefinition.md)

### Extensions

* [AdditionalDetails](StructureDefinition-sact-additional-details.md)
* [Regimen under review](StructureDefinition-sact-additional-plan-status.md)
* [LocationAdministration](StructureDefinition-sact-administration-site.md)
* [Disclaimer](StructureDefinition-sact-disclaimer.md)
* [ESMO-MCBS Score](StructureDefinition-sact-esmo-score.md)
* [LocationMedicationCollection](StructureDefinition-sact-location-medication-collection.md)
* [Off label](StructureDefinition-sact-off-label.md)
* [Instructions for use](StructureDefinition-sact-plan-instructions.md)
* [Regimen type](StructureDefinition-sact-regimen-type.md)
* [Replaced by](StructureDefinition-sact-replaced-by.md)
* [SupportFactor](StructureDefinition-sact-support-factor.md)
* [TimingOfDays](StructureDefinition-sact-timing-of-days.md)
* [TreatmentSetting](StructureDefinition-sact-treatment-setting.md)

### CapabilityStatements

* [Capability Statement describing CCA FHIR APIs](CapabilityStatement-CcaCapabilityStatement.md)

### ImplementationGuides

* [HL7® FHIR® Te Aho o Te Kahu, Cancer Control Agency Implementation Guide](index.md)

### Examples

* [ActCabergoline (ActivityDefinition)](ActivityDefinition-ActCabergoline.md)
* [ActTragacanth (ActivityDefinition)](ActivityDefinition-ActTragacanth.md)
* [LUNG NSCLC Metastatic - alectinib (PlanDefinition)](PlanDefinition-52331000210102.md)
* [LUNG NSCLC NON-Metastatic - alectinib (PlanDefinition)](PlanDefinition-52401000210103.md)
* [GU PROS Castration resistant Metastatic - abiraterone and dexamethasone (PlanDefinition)](PlanDefinition-52451000210102.md)
* [GYN END Adjuvant - cISplatin chemoradiation followed by cARBOplatin and PACLItaxel (PlanDefinition)](PlanDefinition-60071000210106.md)
* [Colorectal Adjuvant FOLFOX (a7) (PlanDefinition)](PlanDefinition-ColoRectal.md)
* [SuperceededPlan (PlanDefinition)](PlanDefinition-SuperceededPlan.md)
